OPKO Health Inc banner

OPKO Health Inc
NASDAQ:OPK

Watchlist Manager
OPKO Health Inc Logo
OPKO Health Inc
NASDAQ:OPK
Watchlist
Price: 1.14 USD 0.88% Market Closed
Market Cap: $865.3m

OPKO Health Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

OPKO Health Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
OPKO Health Inc
NASDAQ:OPK
Research & Development
-$124m
CAGR 3-Years
-19%
CAGR 5-Years
-10%
CAGR 10-Years
-2%
Abbvie Inc
NYSE:ABBV
Research & Development
-$9.1B
CAGR 3-Years
-12%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.7B
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$7.2B
CAGR 3-Years
-17%
CAGR 5-Years
-11%
CAGR 10-Years
-6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-15%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-13%
CAGR 5-Years
-14%
CAGR 10-Years
-12%
No Stocks Found

OPKO Health Inc
Glance View

In the bustling world of healthcare and biotechnology, OPKO Health Inc. stands as a unique and dynamic player. Founded by the ambitious mind of Dr. Phillip Frost, the company has woven itself into the fabric of diverse biomedical sectors. OPKO predicates its enterprise on the integration of complementary businesses ranging from diagnostics to pharmaceuticals, creating synergies that are not just theoretical, but markedly operational. At the heart of its operations lies the interplay between new drug discovery and diagnostics development, allowing OPKO to leverage cutting-edge technologies in crafting novel health solutions. By honing in on significant medical unmet needs, they aspire to deliver innovations that address chronic diseases such as diabetes, oncology, and neurological disorders. This strategic weaving together of distinct healthcare sectors manifests in OPKO's sprawling portfolio—from the renowned Rayaldee, which targets secondary hyperparathyroidism, to its advanced diagnostics segments, which include proprietary tests for specific cancers and other conditions. The company's revenue streams can be best visualized as an interlocking lattice of healthcare services and products. It earns through a blend of product sales, licensing, and collaborative agreements with other biotech and pharmaceutical giants. Rayaldee, as a potent testament to their R&D prowess, contributes robustly to their revenue, while the diagnostics division, powered by their substantial investment in technology and infrastructure, brings in consistent sales from various testing services. The company’s BioReference Laboratories, one of the largest full-service diagnostic laboratories in the U.S., also plays a critical role in their financial architecture, offering both routine and esoteric tests. Additionally, OPKO is involved in strategic collaborations and licensing arrangements, enhancing its market footprint and creating channels for revenue infusion through partnerships with industry leaders. Ultimately, OPKO Health Inc.'s narrative is one of leveraging diversified capabilities and strategic partnerships to carve out a formidable presence in the complex landscape of global healthcare.

OPK Intrinsic Value
1.21 USD
Undervaluation 6%
Intrinsic Value
Price $1.14

See Also

What is OPKO Health Inc's Research & Development?
Research & Development
-124m USD

Based on the financial report for Dec 31, 2025, OPKO Health Inc's Research & Development amounts to -124m USD.

What is OPKO Health Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-2%

Over the last year, the Research & Development growth was -18%. The average annual Research & Development growth rates for OPKO Health Inc have been -19% over the past three years , -10% over the past five years , and -2% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett